Julia Meißner
Impact in
-
- Acute Myocardial Infarction Research
- Heart Failure Treatment and Management
-
- Lymphoma Diagnosis and Treatment
Papers in
-
- Lymphoma Diagnosis and Treatment 46
- Oncology 28
- CAR-T cell therapy research 13
- Co-authors
- Tobias ReichlinRaphael TwerenboldChristian MuellerMiriam ReiterKatrin WinklerPhilip HaafWillibald HochholzerPeter Borchmann
- Journals
- Blood (18 papers)Journal of Clinical Oncology (9 papers)Clinical Chemistry (4 papers)HemaSphere (4 papers)Annals of Oncology (3 papers)
- Partner nations
- GermanySwitzerlandSpain
In The Last Decade
Julia Meißner
65 papers receiving 2.4k citations
Hit Papers
Peers
Comparison fields: 5 of 97
- Cardiology and Cardiovascular Medicine 1.0k
- Pathology and Forensic Medicine 703
- Radiology, Nuclear Medicine and Imaging 572
- Oncology 676
- Internal Medicine 82
Countries citing papers authored by Julia Meißner
This map shows the geographic impact of Julia Meißner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julia Meißner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julia Meißner more than expected).
Fields of papers citing papers by Julia Meißner
This network shows the impact of papers produced by Julia Meißner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julia Meißner. The network helps show where Julia Meißner may publish in the future.
Co-authors
The 25 scholars most cited alongside Julia Meißner, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2024 | 0 | |
| 3 | 2023 | 0 | |
| 4 | 2023 | 1 | |
| 5 | 2023 | 0 | |
| 6 | 2021 | 18 | |
| 7 | 2020 | 0 | |
| 8 | 2020 | 6 | |
| 9 | B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and predniso(lo)Ne) in Older Patients with Advanced-Stage Hodgkin Lymphoma: Results of a Phase II Intergroup Trial By the German Hodgkin Study Group (GHSG) and the Nordic Lymphoma Group (NLG) | 2018 | 0 |
| 10 | 2015 | 20 | |
| 11 | 2013 | 4 | |
| 12 | 2012 | 101 | |
| 13 | 2012 | 12 | |
| 14 | 2011 | 16 | |
| 15 | 2011 | 2 | |
| 16 | 2011 | 25 | |
| 17 | 2010 | 36 | |
| 18 | 2010 | 37 | |
| 19 | 2010 | 10 | |
| 20 | 2004 | 19 |
About Julia Meißner
Julia Meißner is a scholar working on Pathology and Forensic Medicine, Oncology, Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging, having authored 72 papers that have together received 2.5k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (46 papers), Lung Cancer Treatments and Mutations (23 papers), CAR-T cell therapy research (13 papers), Acute Myocardial Infarction Research (12 papers), CNS Lymphoma Diagnosis and Treatment (9 papers), Cardiac Imaging and Diagnostics (8 papers), Heart Failure Treatment and Management (8 papers) and Chronic Lymphocytic Leukemia Research (5 papers). The work is most often cited by research in Cardiology and Cardiovascular Medicine (1.0k citations), Pathology and Forensic Medicine (703 citations), Radiology, Nuclear Medicine and Imaging (572 citations), Oncology (676 citations) and Internal Medicine (82 citations). Julia Meißner has collaborated with scholars based in Germany, Switzerland and Spain. Frequent co-authors include Tobias Reichlin, Raphael Twerenbold, Christian Mueller, Miriam Reiter, Katrin Winkler, Philip Haaf, Willibald Hochholzer, Peter Borchmann, Claudia Stelzig and Michael Fuchs. Their work appears in journals such as Blood, Journal of Clinical Oncology, Clinical Chemistry, HemaSphere and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.